A novel Phase 2 RHB-204 [1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium avium subspecies paratuberculosis infected (MAP-positive) Crohn's disease (CD) ...
(RTTNews) - RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases, announced Wednesday that the European Commission has granted ...
(RTTNews) - RedHill Biopharma Ltd. (RDHL), a specialty biopharmaceutical company, has entered into an exclusive worldwide licensing agreement, excluding North America, with Liège, Belgium-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback